In this edition:
MANIFEST-2: long-term follow-up of pelabresib + ruxolitinib in myelofibrosis
First-in-class pADCs targeting mutant CALR for MPNs
RESTORE: elritercept ± ruxolitinib in myelofibrosis
Ropeginterferon alfa-2b in prefibrotic primary myelofibrosis & low-/intermediate-risk myelofibrosis
IMPROVEMF: imetelstat + ruxolitinib in intermediate-1/-2 or high-risk myelofibrosis
Genotypes at ultra-high risk of progression to blast-phase MPN
Correlates of anaemia response to DISC-0974 (anti-hemojuvelin antibody) in myelofibrosis
Live birth rates in women with MPNs
Ruxolitinib + CPX-351 in advanced-phase MPNs
Pacritinib vs. momelotinib in thrombocytopenic myelofibrosis
Please login below to download this issue (PDF)